Status:
UNKNOWN
Riboflavin at 4ºC for the Management of Pain After Crosslinking for Keratoconus Patients
Lead Sponsor:
Instituto de Oftalmología Fundación Conde de Valenciana
Conditions:
Keratoconus
Crosslinking
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Background: The objective of corneal collagen crosslinking (CXL) is to increase the binding of intrafibrillary and interfibrillary covalent bonds to improve the mechanical stability of the cornea and ...
Eligibility Criteria
Inclusion
- patients of any gender
- older than 18 years
- diagnosis of keratoconus who require management with crosslinking in both eyes for evidence of progression.
Exclusion
- crosslinking without removal of epithelium or unilateral crosslinking.
- patients with other ocular conditions different from keratoconus.
- cognitive disability that limits the compression of the pain test as Down syndrome, etc.
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2019
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT03760770
Start Date
February 1 2018
End Date
February 1 2019
Last Update
November 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto de oftalmología conde de Valenciana
Mexico City, Mexico, 06800